Cargando…
A field based evaluation of adverse events following MenAfriVac(®)vaccine delivered in a controlled temperature chain (CTC) approach in Benin
INTRODUCTION: An estimated one hundred million African meningitis belt residents have received MenAfriVac(®)meningococcal serogroup A conjugate vaccine. Since October 2012 the vaccine has been licensed for use in a controlled temperature chain (CTC) approach, at temperatures of up to 40°C for up to...
Autores principales: | Steffen, Christoph, Tokplonou, Evariste, Jaillard, Philippe, Dia, Roger, Alladji, Marie N'Deye Bassabi, Gessner, Bradford |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The African Field Epidemiology Network
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282804/ https://www.ncbi.nlm.nih.gov/pubmed/25574320 http://dx.doi.org/10.11604/pamj.2014.18.344.3975 |
Ejemplares similares
-
MenAfriVac as an Antitetanus Vaccine
por: Borrow, Ray, et al.
Publicado: (2015) -
Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac
por: Tang, Yuxiao, et al.
Publicado: (2015) -
Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt
por: Karachaliou, Andromachi, et al.
Publicado: (2015) -
Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials
por: Idoko, Olubukola T., et al.
Publicado: (2015) -
Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali
por: Roy Chowdhury, Panchali, et al.
Publicado: (2015)